Vical, Inc.

NASDAQ: VICL
$0.84
+$0.01 (+1.1%)
Closing price August 14, 2020
The top analyst upgrades, downgrades and initiations seen for Monday included Allscripts Healthcare Solutions, AmeriGas Partners, CVS Health, IMAX, Kraft Heinz, Marathon Oil, Microsoft and Pfizer.
Weight Watchers, Estée Lauder, Vical, and e.l.f. Beauty all posted new 52-week lows on Thursday.
The top analyst upgrades, downgrades and other research calls from Monday Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna and Lexicon Pharma.
Here are 10 stocks trading under $10 in which analysts made massive upside calls during the week of July 22.
Most investors either feel the stock market needs a breather or that they are going to find their next real rewards in some of the companies that are not going to just move up or down with the Dow or...
Friday's top analyst upgrades, downgrades and initiations include Citrix Systems, Danaher, Host Hotels, Keurig Green Mountain and Micron Technology.
With the bull market now six years old and with a Federal Reserve expected to finally begin raising interest rates in the months ahead, investors get jittery any time there is a week when stocks sell...
Tuesday's top analyst upgrades, downgrades and initiations include BHP Billiton, Bojangles, Intel, Lululemon Athletica, Palo Alto Networks and Zions Bancorp.
These are the top analyst downgrades, cautious research notes and stocks to sell from Wall Street for Tuesday, August 13, 2013. They include Allot Communications, Microsoft, Vical and First Solar.
Source: Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Friday.Altria Group Inc. (NYSE: MO) raised to Buy with $39 target at...
Vical Inc. (NASDAQ: VICL) is seeing its shares surging higher on news that it has signed a worldwide, nonexclusive licensing pact with drug giant Bristol-Myers Squibb Co. (NYSE: BMY). The pact covers...
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s news...
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
We are entering into the last waves of the normalized quarterly earnings reports for companies with December 31 quarter-end dates, and we are entering the first waves of the earnings reports from...
Each morning 24/7 Wall St. issues a list of some of the key analyst upgrades, downgrades, and initiations seen from Wall Street research firms.  We review these and other calls from the week to see...